Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Equal-Weight rating on Fate Therapeutics (NASDAQ:FATE) and lowered the price target from $6 to $5.
November 09, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Fate Therapeutics and lowered the price target from $6 to $5.
The lowering of the price target by Wells Fargo indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100